Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$587,841.00
Mar 23, 2026
For-profit organization
515716
515716
ProteinQure uses Canadian cloud compute to advance PepQure, an AI diffusion model that designs optimized therapeutic peptides for drug discovery.
$1,800,000.00
Dec 23, 2024
For-profit organization
1018909
1018909
To support the development of new and advanced technologies to create new therapeutics.
$728,000.00
Mar 1, 2024
For-profit organization
UKRI Biomanufacturing - 10101341 Platforms for GPCRs - Novel technology platforms for computational design and cell-based screening of peptide libraries targeting orphan GPCRs
1016558
As part of the international consortium project “Platforms for GPCRs - Novel technology platforms for computational design and cell-based screening of peptide libraries targeting orphan GPCRs”, this project will focus on ProteinQure and Orbit Discovery developing a new discovery platform for peptide therapeutics to drug previously undruggable, orphan G-Protein Coupled Receptors (GPCRs). The result will be new capabilities and products for ProteinQure to market. ProteinQure's Artificial Intelligence platform will design custom libraries containing over 500K peptides, and these peptides will be screened using Orbit Discovery’s platform. We will demonstrate the ability to drug orphan GPCRs, one of the hardest classes of disease targets.
$2,880.00
Feb 29, 2024
For-profit organization
CIIP PDA – ProteinQure Inc – 2023-24
7457722 P014168001
The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research and development collaboration that has good potential for commercialization.
$15,000.00
Jan 12, 2024
For-profit organization
Develop digital adoption plan
$4,455.00
Oct 7, 2023
For-profit organization
CIIP PDA – ProteinQure Inc. – 2023-24
7453861 P013584001
The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research and development collaboration that has good potential for commercialization.
$206,800.00
Aug 16, 2023
For-profit organization
In vivo validation of ProteinQure’s SORT1 delivery platform for triple negative breast cancer in patient relevant Trodelvy resistant animal models
1010963
ProteinQure is going to show the potential of its SORT1 delivery platform by demonstrating the ability to cure Trodelvy/Enhertu resistant Triple Negative Breast Cancer (the most deadly form of breast cancer with no treatments). This IRAP project will involve the design and creation of animal models based on patient samples (PDX) which recapitulate acquired resistance to Trodelvy/Enhertu. While simpler PDX models would be sufficient for regulatory purposes, more advanced models increase the commercial potential and likelihood of success for the SORT1 platform in TNBC.
$700,000.00
Jan 1, 2023
For-profit organization
1003630
1003630
To develop novel quantum algorithms to help improve the quality of their supervised machine learning models for drug simulations.
$470,000.00
Nov 15, 2021
For-profit organization
Internal Target Selection and Prosecution
983646
ProteinQure is planning to pursue 2 internal drug discovery programs. Starting with five targets we have researched extensively we will perform two core activities to help select two internal targets as finalists. Those two activities are validating experimental literature finding and computational validation of initial structural models. We will then design the first generation of molecules for those two specific disease targets using our computational platform and test them via contractors. The resulting molecules will be key for future fundraising efforts and eventually be commercialized (by selling them to partners).
$70,449.00
Dec 20, 2020
For-profit organization
Innovation Assistance Program – Round 2.5
966000
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.